Insider Transactions in Q1 2024 at Supernus Pharmaceuticals, Inc. (SUPN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
14,491
-62.84%
|
$507,185
$35.31 P/Share
|
|
Mar 21
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,491
+38.59%
|
$362,275
$25.3 P/Share
|
|
Mar 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
400
-4.46%
|
$14,000
$35.31 P/Share
|
|
Mar 20
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+4.27%
|
$10,000
$25.3 P/Share
|
|
Mar 19
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
12,364
-59.06%
|
$432,740
$35.31 P/Share
|
|
Mar 19
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,364
+37.13%
|
$309,100
$25.3 P/Share
|
|
Mar 13
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
62,366
-78.1%
|
$2,058,078
$33.79 P/Share
|
|
Mar 13
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
62,366
+43.84%
|
$1,122,588
$18.49 P/Share
|
|
Mar 12
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
3,884
-31.19%
|
$124,288
$32.99 P/Share
|
|
Mar 12
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,884
+23.77%
|
$46,608
$12.98 P/Share
|
|
Feb 28
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,788
-1.8%
|
$453,276
$27.94 P/Share
|
|
Feb 28
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+3.62%
|
-
|
|
Feb 28
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
460
-5.58%
|
$12,420
$27.94 P/Share
|
|
Feb 28
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
990
+10.73%
|
-
|
|
Feb 26
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
5,000
-36.85%
|
$150,000
$30.21 P/Share
|
|
Feb 26
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.93%
|
$45,000
$9.13 P/Share
|
|
Feb 23
2024
|
Frederick M. Hudson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+9.48%
|
-
|
|
Feb 23
2024
|
Georges Gemayel Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+18.43%
|
-
|
|
Feb 23
2024
|
Carrolee Barlow Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+18.43%
|
-
|
|
Feb 23
2024
|
Charles W Newhall Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+3.11%
|
-
|
|
Feb 23
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
485
-0.55%
|
$14,065
$29.06 P/Share
|
|
Feb 23
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+1.41%
|
-
|
|
Feb 23
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
567
-10.89%
|
$16,443
$29.06 P/Share
|
|
Feb 23
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+19.36%
|
-
|
|
Feb 23
2024
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-15.45%
|
$38,106
$29.06 P/Share
|
|
Feb 23
2024
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+22.72%
|
-
|
|
Feb 23
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-6.93%
|
$18,502
$29.06 P/Share
|
|
Feb 23
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+11.95%
|
-
|
|
Feb 23
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
937
-11.45%
|
$27,173
$29.06 P/Share
|
|
Feb 23
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
1,875
+18.64%
|
-
|
|
Feb 23
2024
|
John M Siebert Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,886
+4.23%
|
-
|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
246
-0.28%
|
$6,642
$27.94 P/Share
|
|
Feb 22
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
750
+0.86%
|
-
|
|
Feb 22
2024
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
500
+7.69%
|
-
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-5.04%
|
$9,045
$27.94 P/Share
|
|
Feb 22
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
750
+10.14%
|
-
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-4.47%
|
$10,044
$27.94 P/Share
|
|
Feb 22
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
750
+8.26%
|
-
|
|
Feb 22
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-7.11%
|
$8,181
$27.94 P/Share
|
|
Feb 22
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750
+14.97%
|
-
|
|
Feb 12
2024
|
Jack A. Khattar President, CEO |
SELL
Other acquisition or disposition
|
Indirect |
16,500
-1.59%
|
-
|
|
Feb 12
2024
|
Jack A. Khattar President, CEO |
BUY
Other acquisition or disposition
|
Direct |
16,500
+1.81%
|
-
|
|
Jan 10
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
8,000
-8.54%
|
$216,000
$27.91 P/Share
|
|
Jan 10
2024
|
Tami Tillotson Martin Sr. V.P., Regulatory Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.87%
|
$72,000
$9.24 P/Share
|